On March 10, 2022 NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, reported that new preclinical data for the company’s lead asset NT-I7 (efineptakin alfa) will be presented during poster sessions at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) annual meeting, to be held in New Orleans on April 8-13, 2022 (Press release, NeoImmuneTech, MAR 10, 2022, View Source [SID1234609923]). The data come from two studies evaluating NT-I7, a novel long-acting human IL-7, 1. in combination with hIL-2/TCB2c complex, and 2. in combination with anti-TIGIT or anti-VEGF therapies.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details related to the poster presentations are as follows:
Title: rhIL-7-hyFc (efineptakin alpha; NT-I7) enhances the anti-tumor response when combined with hIL-2/TCB2c complex
Lead Author: Seungtae Baek, Research Institute of NeoImmuneTech
Abstract Number: 4199
Poster Session: Combination Immunotherapies 2
Title: rhIL-7-hyFc (efineptakin alpha; NT-I7) enhances the anti-tumor response when combined with anti-TIGIT or anti-VEGF
Lead Author: Seungtae Baek, Research Institute of NeoImmuneTech
Abstract Number: 4172
Poster Session: Combination Immunotherapies 1
About NT-I7
NT-I7 (efineptakin alfa) is the only clinical-stage long-acting human IL-7, and is being developed for oncologic and immunologic indications, in which T cell amplification and enhanced functionality may provide clinical benefit. IL-7 is a fundamental cytokine for naïve and memory T cell development and for sustaining immune response to chronic antigens (as in cancer) or foreign antigens (as in infectious diseases). In clinical trials to date, NT-I7 has exhibited favorable PK/PD and safety profiles, both as a monotherapy and in combination with other anticancer treatments. NT-I7 is being studied in multiple clinical trials in solid tumors and as a vaccine adjuvant. Studies are being planned for testing in hematologic malignancies, additional solid tumors and other immunology-focused indications.